AstraZeneca PLC American Depositary Shares (AZN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
AstraZeneca Beats on Q3 Earnings, Ups 2024 View, to Invest $3.5B in US
AZN beats third-quarter estimates for earnings and sales. It raises its sales and profit outlook for 2024 for the second time this year.
Levi & Korsinsky Announces an Investigation on Behalf of AstraZeneca PLC (AZN) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESSWIRE / November 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that a fraud investigation into AstraZeneca has expanded to include several agencies of the Chinese government, implicating dozens of senior executives at the Company.
AstraZeneca PLC (AZN) Q3 2024 Earnings Call Transcript
AstraZeneca PLC (NASDAQ:AZN ) Q3 2024 Earnings Conference Call November 12, 2024 9:00 AM ET Company Participants Andy Barnett - Head, Investor Relations Pascal Soriot - Executive Director and CEO Aradhana Sarin - Executive Director and CFO Dave Fredrickson - Executive Vice President, Oncology Business Susan Galbraith - Executive Vice President, Oncology Research and Development Ruud Dobber - Executive Vice President and President, BioPharmaceuticals Sharon Barr - Executive Vice President, BioPharmaceuticals Research and Development Marc Dunoyer - Chief Executive Officer, Alexion and CSO, AstraZeneca Conference Call Participants James Gordon - JPMorgan Richard Parkes - BNP Paribas Exane Sachin Jain - Bank of America Christopher Uhde - SEB Gonzalo Artiach - Danske Bank Steve Scala - Cowen Rajan Sharma - Goldman Sachs Etzer Darout - BMO Simon Baker - Redburn Emmanuel Papadakis - Deutsche Bank Mattias Haggblom - Handelsbanken Eric Le Berrigaud - Stifel Rajesh Kumar - HSBC Gonzalo Artiach - Danske Bank Peter Welford - Jefferies Luisa Hector - Berenberg Capital Markets Emily Field - Barclays Operator Good morning to those joining from the U.S., good afternoon to those in the U.K. and Central Europe, and good evening to those listening in Asia. Welcome ladies and gentlemen to AstraZeneca's Nine Months and Q3 Results 2024 Webinar for Investors and Analysts.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC - AZN
NEW YORK, NY / ACCESSWIRE / November 12, 2024 / Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ:AZN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
AstraZeneca Lifts Outlook, Plans $3.5B US Investment
British drugmaker AstraZeneca (AZN) increased its full-year sales outlook on booming demand for its cancer and rare-disease drugs, and said it plans to invest $3.5 billion in its U.S. business by the end of 2026.
Here's What Key Metrics Tell Us About Astrazeneca (AZN) Q3 Earnings
Although the revenue and EPS for Astrazeneca (AZN) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
AstraZeneca Lifts 2024 Forecast On Better Than Expected Q3 Performance, Says It Takes China Investigations 'Very Seriously'
AstraZeneca Plc AZN reported third-quarter sales of $13.57 billion, up 18% year over year (+21% at constant currency), beating the consensus of $13.09 billion.
AstraZeneca: 450 million pound investment in UK under review amid talks with govt
London-listed drugmaker AstraZeneca said its plan to invest 450 million pounds ($576.7 million) in Britain for vaccine research and development, announced in March, is under review while talks with the government over incentives continue.
AstraZeneca boss says China arrests taken ‘very seriously'
AstraZeneca PLC (LSE:AZN) chief executive Pascal Soriot has signalled the company is taking a criminal probe into its Chinese business “very seriously”. Soriot on Tuesday said AstraZeneca would “fully cooperate” with Chinese authorities over the case, which has seen China president Leon Wang detained.
AstraZeneca Lifts Outlook, Plans $3.5B US Investment
British drugmaker AstraZeneca (AZN) increased its full-year sales outlook on booming demand for its cancer and rare-disease drugs, and said it plans to invest $3.5 billion in its U.S. business by the end of 2026.
Shareholder Rights Advocates at Levi & Korsinsky Investigate AstraZeneca PLC (AZN) Regarding Possible Securities Fraud Violations
NEW YORK, NY / ACCESSWIRE / November 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that a fraud investigation into AstraZeneca has expanded to include several agencies of the Chinese government, implicating dozens of senior executives at the Company.
AstraZeneca upgrades outlook for the second time on four months
AstraZeneca PLC (LSE:AZN) raised its 2024 sales and profit outlook for the second time in under four months, following stronger-than-expected third-quarter results. The Anglo-Swedish drugs giant now projects that annual revenue and core earnings per share will increase by a high-teens percentage, up from a previous forecast of mid-teens growth, based on constant currency rates.
